Latent TGF-beta 1

Latent TGF-beta 1

Latent TGF-beta 1 Overview

Molecule Name
Transforming growth factor beta 1
Synonyms
Latent TGF-beta 1,Latent TGFB1,TGFB1,CED,DPD1,LAP,TGF-beta-1,TGFB
Drug Development Progress
Drugs in Clinical Trials22
Approved Drugs1
Highest Development StageApproved
Target Synonym
Latency-Associated Peptide,IBDIMDE,Transforming Growth Factor beta1,Prepro-Transforming Growth Factor Beta-1,TGF-Beta-1,Transforming Growth Factor, Beta 1,CED,TGFB,DPD1,TGFB1,Transforming Growth Factor Beta-1 Proprotein,Camurati-Engelmann Disease,LAP,TGFbeta,Transforming Growth Factor Beta 1,Diaphyseal Dysplasia 1, Progressive,TGF-Beta1
Background
Transforming growth factor beta 1 ( TGFB1) is also known as TGF-β1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I and Decorin.

Latent TGF-beta 1 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
VactosertibTEW-7197; EW-7197; NOV-1301Phase 3 ClinicalMedpacto Inc
Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Osteosarcoma; Solid tumours; Stomach Neoplasms; Urologic Neoplasms
Details
Bintrafusp alfaM-7824; GSK-4045154; MSB-0011359CPhase 3 ClinicalMerck Serono
Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop
Details
NisevokitugNIS-793Phase 3 ClinicalXoma Corp
Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential
Details
Yinfenidone HydrochlorideHEC-585; HEC-00000585Phase 3 ClinicalHec Pharm Co Ltd
Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis
Details
SB-01 (Ensol BioSciences)Peniel-2000; SB-01; Peniel 2K; YH14618; YH-14618; P2KPhase 3 ClinicalEnsol Biosciences Inc
Intervertebral Disc Degeneration; Intervertebral disc disease; Low Back Pain
Details
LivmoniplimabMGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115Phase 3 ClinicalArgenx Se
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours
Details
Dalutrafusp alfaGS-1423; AGEN-1423Phase 2 ClinicalAgenus Inc
Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
ZSP-1603ZSP-1603Phase 2 ClinicalGuangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Liver Neoplasms; Ovarian Neoplasms; Solid tumours; Thyroid Neoplasms
Details
NicousamideXLF-III-43Phase 2 ClinicalInstitue Of Materia Medica Chinese Academy Of Medical Science
Diabetic Nephropathies; Hypertensive nephropathy
Details
Meflonidone hydrochloridePhase 2 ClinicalCentral South University, Guangzhou Nanxin Pharma Co Ltd
Diabetes Mellitus, Type 2; Diabetic Nephropathies
Details
FluorofenidoneAKF-PDPhase 2 ClinicalCentral South University, Dierepharma HK Ltd, Hainan Haiyao Co Ltd
Hepatitis B, Chronic; Liver Cirrhosis
Details
CotsiranibSTP-705LU; STP-705LV; STP-705; STP-705LPhase 2 ClinicalSirnaomics, Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd
Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cicatrix, Hypertrophic; Keloid; Liver Neoplasms; Obesity, Abdominal
Details
YL-13027YL-13027Phase 2 ClinicalYL-Pharma
Pancreatic Neoplasms; Solid tumours
Details
MR-001MR001; MR-001Phase 2 ClinicalShenzhen Maijiarui Biotechnology Co Ltd
Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
Details
LinavonkibartSRK-181; SRT-BETA-1-AB3Phase 1 ClinicalScholar Rock Inc
Neoplasms
Details
Charis-1000Charis-1000; C 1K; C1KPhase 1 ClinicalEnsol Biosciences Inc
Breast Neoplasms
Details
HLX-6018HLX-6018; HLX6018Phase 1 Clinical
Idiopathic Pulmonary Fibrosis
Details
RO7496353RO7496353; RO-7496353; SOF 10; RG6440; RG-6440Phase 1 ClinicalGenentech Inc
Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Solid tumours; Stomach Neoplasms
Details
JYB-1907JYB-1907Phase 1 ClinicalJiangxi Jemincare Group Co Ltd
Solid tumours
Details
STP-707STP-707; STP707Phase 1 ClinicalSirnaomics Biopharmaceuticals (Suzhou) Co Ltd
Cholangitis, Sclerosing; Liver Cirrhosis; Liver Neoplasms; Pancreatic Neoplasms; Pulmonary Fibrosis; Solid tumours
Details
PXS-64PXS-64Phase 1 ClinicalSyntara Ltd
Multiple Sclerosis
Details
BMS-986416BMS-986416; AVID-200 DP; AVID-200Phase 1 ClinicalFormation Biologics Corp
Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Solid tumours; Thrombocythemia, Essential
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Tonogenchoncel-LTG-CApprovedTissuegeneInvossa-K, InvossaSouth KoreaOsteoarthritisnull2017-07-01
Intervertebral Disc Degeneration; Osteoarthritis; Osteoarthritis, Knee
Details